A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

This publication has 17 references indexed in Scilit:

• Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases
  Antimicrobial Agents and Chemotherapy, 2002
• A Randomized Double‐Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal Esophagitis
  Clinical Infectious Diseases, 2001
• Epidemiology of Human Immunodeficiency Virus–Associated Opportunistic Infections in the United States in the Era of Highly Active Antiretroviral Therapy
  Clinical Infectious Diseases, 2000
• Practice Guidelines for the Treatment of Candidiasis
  Clinical Infectious Diseases, 2000
• International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
  Diagnostic Microbiology and Infectious Disease, 1999
• Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine
  Mayo Clinic Proceedings, 1998
• Activity of MK-0991 (l-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
  Diagnostic Microbiology and Infectious Disease, 1998
• Failure of All Antifungal Therapy for Infection Due toCandida albicans. A New AIDS‐Related Problem?
  Clinical Infectious Diseases, 1998
• Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
  Clinical Infectious Diseases, 1996
• Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance
  The American Journal of Medicine, 1994